ArticleTherapeutic advances in vaccines2013
An update on vaccines against Shigella.
Article in Therapeutic advances in vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04056117 (Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants
Who cites it
29 citing papers in PubMed.
- Development of a multi-epitope vaccine against Helicobacter pylori using a novel saRNA technology through an immunoinformatics approach.Scientific reports · 2025Article
- High pathogenic potential of Shigella flexneri strains descending from a common ancestor isolated over 34 years in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Development of a Novel mRNA Vaccine AgainstBioinformatics and biology insights · 2025Article
- Safety and Tolerability of ShigActive™, aAntibiotics (Basel, Switzerland) · 2024Article
- Investigation of the vaccine potential of anVaccine: X · 2024Article
- A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuatedFrontiers in microbiology · 2024Article
- The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives.Vaccines · 2023Review
- Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in theVaccines · 2022Review
- The Ongoing Journey of aVaccines · 2022Review
- Identification of vaccine and drug targets in Shigella dysenteriae sd197 using reverse vaccinology approach.Scientific reports · 2022Article
- Application of Reverse Vaccinology and Immunoinformatic Strategies for the Identification of Vaccine Candidates Against Shigella flexneri.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Early Childhood Shigellosis and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study with a Prolonged Follow-up.Journal of attention disorders · 2021Article
- Review
- Shigella sonnei: virulence and antibiotic resistance.Archives of microbiology · 2021Review
- Article
- Shigella flexneri: an emerging pathogen.Folia microbiologica · 2020Review
- Synthetic carbohydrate-based vaccines: challenges and opportunities.Journal of biomedical science · 2020Review
- Reverse vaccinology approach for the identification and characterization of outer membrane proteins ofClinical and experimental vaccine research · 2020Article
- A tale of two bacterial enteropathogens and one multivalent vaccine.Cellular microbiology · 2019Review
- PCR-Based Method for Shigella flexneri Serotyping: International Multicenter Validation.Journal of clinical microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite intensive research efforts for more than 60 years, utilizing diverse vaccine strategies, a safe and efficacious vaccine against shigellosis is not available yet. We are currently witnessing innovative approaches based on elucidation of the virulence mechanisms of Shigella, understanding the immune response to the pathogen and progress in molecular technology for developing Shigella vaccines. It is hoped that these will lead to a licensed effective Shigella vaccine to protect humans against the significant worldwide morbidity and mortality caused by this microorganism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.